NEW BRUNSWICK, N.J., June 30 /PRNewswire-FirstCall/ -- Johnson & Johnson JNJ announced today that Janssen Pharmaceutica N.V., a Johnson & Johnson company, has entered into a collaboration with Vertex Pharmaceuticals Incorporated VRTX to develop and commercialize Vertex's investigational hepatitis C virus (HCV) protease inhibitor, VX-950. Under the agreement, Janssen will have exclusive rights in Europe, South America, the Middle East, Africa and Australia. Vertex will retain exclusive commercial rights to VX-950 in North America. Tibotec Pharmaceuticals, Ltd., another Johnson & Johnson company, will lead the development and commercialization of VX-950 for Janssen.
Terms of the Agreement
Terms of the transaction include a before-tax upfront payment of $165 million, which will be expensed in the second quarter. In addition, there will be additional payments contingent upon successful development, approval and launch of VX-950 in the regions where Janssen has commercial rights and reimbursement of certain drug development costs. The agreement also includes a royalty on product sales in Europe, South America, the Middle East, Africa and Australia.
The Company anticipates that the $165 million payment will largely be offset by other non-recurring gains recognized over the balance of the year. Therefore, this transaction is not expected to impact full year guidance.
Ron